Risk of amyloidosis associated with SpA and subtypes of SpA
| Without amyloidosis | With amyloidosis | Crude OR | 95% CI | AOR | 95% CI | |||
| N (%) | 213 414 (99.6) | 860 (0.4) | ||||||
| Non-SpA (%) | 107 066 (99.9) | 68 (0.1) | ref | ref | ||||
| SpA (%) | 106 348 (99.3) | 792 (0.7) | 10.7 | 8.4 | 13.6 | 10.4 | 8.2 | 13.3 |
| AS (%) | 61 837 (99.3) | 454 (0.7) | 10.6 | 8.3 | 13.5 | 10.0 | 7.8 | 12.8 |
| PsA (%) | 37 132 (99.4) | 237 (0.6) | 9.2 | 7.1 | 11.9 | 9.5 | 7.3 | 12.4 |
| SpA-IBD (%) | 5238 (98.5) | 81 (1.5) | 22.3 | 16.3 | 30.7 | 22.9 | 16.6 | 31.7 |
| ReA (%) | 2141 (99.1) | 20 (0.9) | 13.5 | 8.2 | 22.1 | 10.1 | 6.1 | 16.7 |
OR adjusted by: sex, age, year of admission, Charlson index, readmission, infectious diseases, cardiovascular disease, hypertension, smoking, diabetes mellitus, HCV, HBV, depression, obesity, tuberculosis, osteoporosis, axial surgery and uveitis.
AOR, adjusted OR; AS, ankylosing spondylitis; PsA, psoriatic arthritis; ReA, reactive arthritis; SpA, spondyloarthritis; SpA-IBD, SpA-associated inflammatory bowel disease.